AIM ImmunoTech, Ampligen, Rintatolimod, Pancreatic Cancer, Metastatic Pancreatic Cancer, DURIPANC, Phase 2, Durvalumab, Imfinzi, TLR3,

OCALA, Fla. — October 1, 2026 AIM ImmunoTech Inc. highlighted recent biotech media coverage surrounding its development strategy for...